Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.

Abstract:

:Hyperprolactinemia has been associated with impaired metabolism, including insulin resistance. However, the metabolic effects of elevated prolactin (PRL) levels are not completely clarified. The aim of this study was to obtain more insights of metabolic consequences in hyperprolactinemia patients. Fourteen consecutive patients, eight women and six men, aged 39.7 (±13.7) years with prolactinomas (median PRL 72 [49-131] μg/L in women and 1,260 [123-9,600] μg/L in men) were included. Anthropometric data and metabolic values were studied before and after 2 and 6 months on DA agonists (Bromocriptine [5.7 (±3.9) mg/day, n = 13] or Cabergoline [0.5 mg/week, n = 1]). Euglycemic hyperinsulinemic clamps were studied in six patients before and after 6 months of treatment. PRL normalized in all patients. Anthropometric data changed only in males with a significant decrease of median body weight (95.6 [80.7-110.1] to 83.4 [77.8-99.1] kg, P = 0.046), waist circumference and fat percentage after 6 months. LDL cholesterol was positively correlated to PRL at diagnosis (r = 0.62, P = 0.025) and decreased within 2 months (3.4 [±0.9] to 2.9 [±0.6] mmol/L, P = 0.003). Insulin, IGFBP-1 and total adiponectin levels did not change. Insulin sensitivity tended to improve after 6 months; M-value from 5.7 (±1.8) to 7.8 (±2.6) mg/kg/min, P = 0.083 and per cent improvement in M-value was correlated to per cent reduction in PRL levels (r = -0.85, P = 0.034). In conclusion, beneficial metabolic changes were seen in prolactinoma patients after treatment with DA agonists, underscoring the importance of an active treatment approach and to consider the metabolic profile in the clinical management of hyperprolactinemia patients.

journal_name

Pituitary

journal_title

Pituitary

authors

Berinder K,Nyström T,Höybye C,Hall K,Hulting AL

doi

10.1007/s11102-010-0277-9

subject

Has Abstract

pub_date

2011-09-01 00:00:00

pages

199-207

issue

3

eissn

1386-341X

issn

1573-7403

journal_volume

14

pub_type

临床试验,杂志文章
  • Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125.

    abstract::Glucocorticoids are important immunosuppressive hormones; these steroids also inhibit somatic growth by decreased growth hormone (GH) secretion and induced protein catabolism. The ability of ghrelin, the endogenous ligand for the GHS-1a receptor, to increase body weight is attributed to a combination of enhanced food ...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-007-0054-6

    authors: Tulipano G,Taylor JE,Halem HA,Datta R,Dong JZ,Culler MD,Bianchi I,Cocchi D,Giustina A

    更新日期:2007-01-01 00:00:00

  • Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center.

    abstract:PURPOSE:Long-acting somatostatin analogs are one of the main classes of medical therapy used for acromegaly and most patients require ongoing treatment. Few studies have evaluated the long-term efficacy and safety of lanreotide depot beyond 2 years. The goal of this study was to provide a long-term longitudinal assessm...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-016-0724-3

    authors: Sagvand BT,Khairi S,Haghshenas A,Swearingen B,Tritos NA,Miller KK,Klibanski A,Nachtigall LB

    更新日期:2016-08-01 00:00:00

  • Acromegaly secondary to an incidentally discovered growth-hormone-releasing hormone secreting bronchial carcinoid tumour associated to a pituitary incidentaloma.

    abstract::In this report we emphasize the opportunity of considering the uncommon causes of chronic GH-excess in the initial diagnostic process, such as GHRH hypersecretion, especially in the presence of ambiguous pituitary neuroimaging. This topic may have an important clinical significance in order to plan the most cost-effec...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-008-0146-y

    authors: Verrua E,Ronchi CL,Ferrante E,Ferrari DI,Bergamaschi S,Ferrero S,Zatelli MC,Branca V,Spada A,Beck-Peccoz P,Lania AG

    更新日期:2010-09-01 00:00:00

  • Pituitary lymphoma: a case report and literature review.

    abstract::We report the case of a B-cell type pituitary lymphoma in a 65 year-old male immunocompetent patient who presented with hypogonadotropic hypogonadism and central hypothyroidism and subsequently developed pulmonary lymphoma. Only three cases of pituitary lymphoma have been previously reported, one in a patient with acq...

    journal_title:Pituitary

    pub_type: 杂志文章,评审

    doi:10.1023/a:1009969417380

    authors: Mathiasen RA,Jarrahy R,Cha ST,Kovacs K,Herman VS,Ginsberg E,Shahinian HK

    更新日期:2000-05-01 00:00:00

  • IGF-I assays: current assay methodologies and their limitations.

    abstract::The diagnosis of disorders of growth hormone (GH) is dependent upon accurate measurement of insulin-like growth factor-I (IGF-I) concentrations since serum IGF-I assays have been found to be useful as a screening tests for the presence of growth hormone deficiency (GHD) in children and in both children and adults they...

    journal_title:Pituitary

    pub_type: 杂志文章,评审

    doi:10.1007/s11102-007-0032-z

    authors: Clemmons DR

    更新日期:2007-01-01 00:00:00

  • Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly.

    abstract::Most patients with acromegaly have some degree of insulin resistance. The principal mediator of insulin resistance in acromegaly is hypersecretion of growth hormone. Growth hormone acts at several levels to block insulin actions including inhibiting phosphorylation of the insulin receptor and one of its principal sign...

    journal_title:Pituitary

    pub_type: 杂志文章,评审

    doi:10.1023/a:1023321421760

    authors: Clemmons DR

    更新日期:2002-01-01 00:00:00

  • "Micromegaly": an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era.

    abstract:PURPOSE:Approximately 25 % of cases of clinically active acromegaly cases treated in our academic center between 1996 and 2000, were diagnosed in patients who had elevated plasma IGF-1 levels, but apparently "normal" 24-h mean plasma GH levels. The current study served to update the data for patients with acromegaly re...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-016-0735-0

    authors: Butz LB,Sullivan SE,Chandler WF,Barkan AL

    更新日期:2016-12-01 00:00:00

  • Pituitary xanthogranulomas: clinical features, radiological appearances and post-operative outcomes.

    abstract:BACKGROUND:Xanthogranulomas are inflammatory masses most commonly found at peripheral sites such as the skin. Sellar and parasellar xanthogranulomas are rare and present a diagnostic challenge as they are difficult to differentiate from other sellar lesions such as craniopharyngiomas and Rathke's cleft cysts pre-operat...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-017-0859-x

    authors: Ved R,Logier N,Leach P,Davies JS,Hayhurst C

    更新日期:2018-06-01 00:00:00

  • Aerosolisation in endonasal endoscopic pituitary surgery.

    abstract:PURPOSE:To determine the particle size, concentration, airborne duration and spread during endoscopic endonasal pituitary surgery in actual patients in a theatre setting. METHODS:This observational study recruited a convenience sample of three patients. Procedures were performed in a positive pressure operating room. ...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-021-01125-8

    authors: Dhillon RS,Nguyen LV,Rowin WA,Humphries RS,Kevin K,Ward JD,Yule A,Phan TD,Zhao YC,Wynne D,McNeill PM,Hutchins N,Scott DA

    更新日期:2021-01-19 00:00:00

  • Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly?

    abstract::Oral estrogens reduce GH-induced IGF-1 production and preliminary studies have shown that adjuvant estroprogestin (EP) therapy with octreotide LAR may control disease activity in some female patients who are partially responsive to octreotide LAR. Our aim was to verify if EP alone or in combination with octreotide LAR...

    journal_title:Pituitary

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11102-010-0236-5

    authors: Vallette S,Serri O

    更新日期:2010-12-01 00:00:00

  • The metabolic consequences of thyroxine replacement in adult hypopituitary patients.

    abstract::The metabolic consequences of thyroxine replacement in patients with central hypothyroidism (CH) need to be evaluated. The aim was to examine the outcome of thyroxine replacement in CH. Adult hypopituitary patients (n = 1595) with and without CH from KIMS (Pfizer International Metabolic Database) were studied before a...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-011-0356-6

    authors: Filipsson Nyström H,Feldt-Rasmussen U,Kourides I,Popovic V,Koltowska-Häggström M,Jonsson B,Johannsson G

    更新日期:2012-12-01 00:00:00

  • Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.

    abstract:PURPOSE:Endogenous Cushing's syndrome (CS) is a rare disease that results from exposure to high levels of cortisol; Cushing's disease (CD) is the most frequent form of CS. Patients with CS suffer from a variety of comorbidities that increase the risk of mortality. Surgical resection of the disease-causing lesion is gen...

    journal_title:Pituitary

    pub_type: 杂志文章,评审

    doi:10.1007/s11102-016-0742-1

    authors: Fleseriu M,Castinetti F

    更新日期:2016-12-01 00:00:00

  • Acute administration of alprazolam, a benzodiazepine activating GABA receptors, inhibits cortisol secretion in patients with subclinical but not overt Cushing's syndrome.

    abstract::The purpose of this study is to verify whether acute pre-treatment with alprazolam (ALP), a benzodiazepine that inhibits HPA secretion in normal subjects, could better characterize patients with subclinical Cushing's syndrome (SCS) than the 1-mg dexamethasone test (DST). In 22 patients with SCS, 10 with overt Cushing'...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-012-0433-5

    authors: Giordano R,Berardelli R,Karamouzis I,D'Angelo V,Picu A,Zichi C,Fussotto B,Manzo M,Mengozzi G,Ghigo E,Arvat E

    更新日期:2013-09-01 00:00:00

  • Cis-unsaturated free fatty acids block VIP-mediated GH and PRL secretion by perturbing the cAMP/protein kinase A pathway.

    abstract::Cis-unsaturated free fatty acids (FFA) like oleic acid are strong blockers of both basal and stimulated GH secretion in vivo by acting directly on the somatotroph cell. Several lines of evidence suggest that this inhibitory action is the result of a perturbation of the function of several plasma membrane integral prot...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1023/a:1009962624036

    authors: Pérez FR,Camiña JP,Menéndez C,Beiras A,Casabiell X,Casanueva FF

    更新日期:1998-04-01 00:00:00

  • Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche?

    abstract:INTRODUCTION:Early disease onset, clinical manifestation, histomorphology, and increased tendency to relapse distinguish the adamantinomatous craniopharyngioma (adaCP) from the more favorable papillary variant (papCP). A molecular hallmark of adaCP is the activated Wnt signaling pathway indicated by nuclear β-catenin a...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-013-0543-8

    authors: Hölsken A,Stache C,Schlaffer SM,Flitsch J,Fahlbusch R,Buchfelder M,Buslei R

    更新日期:2014-12-01 00:00:00

  • Dopamine resistance of prolactinomas.

    abstract::Resistance to dopamine agonists can be defined with respect to failure to normalize PRL levels and failure to decrease tumor size by > or = 50%. Using these definitions, failure to normalize PRL levels is seen in 24% of those treated with bromocriptine, 13% of those treated with pergolide and 11% of those treated with...

    journal_title:Pituitary

    pub_type: 杂志文章,评审

    doi:10.1023/a:1026225625897

    authors: Molitch ME

    更新日期:2003-01-01 00:00:00

  • Adverse anthropometric risk profile in biochemically controlled acromegalic patients: comparison with an age- and gender-matched primary care population.

    abstract::GH and IGF-1 play an important role in the regulation of metabolism and body composition. In patients with uncontrolled acromegaly, cardiovascular morbidity and mortality are increased but are supposed to be normalised after biochemical control is achieved. We aimed at comparing body composition and the cardiovascular...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-010-0218-7

    authors: Dimopoulou C,Sievers C,Wittchen HU,Pieper L,Klotsche J,Roemmler J,Schopohl J,Schneider HJ,Stalla GK

    更新日期:2010-09-01 00:00:00

  • Proliferation markers in different types of clinically non-secreting pituitary adenomas.

    abstract::160 clinically non-secreting pituitary adenomas were examined in regard to their expression of the markers PCNA, bcl2, Ki 67 in the mib-1 modification and p53 which are still under investigation for their relevance to cell proliferation. The series contained 60 null cell adenomas, 60 oncocytomas and 40 gonadotroph ade...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1023/a:1009933820856

    authors: Schreiber S,Saeger W,Lüdecke DK

    更新日期:1999-05-01 00:00:00

  • Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.

    abstract:CONTEXT:Somatostatin (SST) and dopamine (DA) inhibit growth hormone (GH) secretion and proliferation of GH-secreting pituitary adenomas (GHomas) through binding to SSTR2 and D2R receptors. Chimeric SST-DA compounds (Dopastatins) display increased potency in inhibiting GH secretion, as compared with individual SST or DA...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-020-01113-4

    authors: Cuny T,Graillon T,Defilles C,Datta R,Zhang S,Figarella-Branger D,Dufour H,Mougel G,Brue T,Landsman T,Halem HA,Culler MD,Barlier A,Saveanu A

    更新日期:2021-01-12 00:00:00

  • Endoscopic endonasal approach for pituitary adenomas: a series of 555 patients.

    abstract:PURPOSE:To report the results of a consecutive series of patients who underwent an endoscopic endonasal approach (EEA) for resection of a pituitary adenoma and compare them to previous series of microscopic and endoscopic approaches. METHODS:A retrospective review of clinical and radiographic outcomes of a consecutive...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-013-0502-4

    authors: Paluzzi A,Fernandez-Miranda JC,Tonya Stefko S,Challinor S,Snyderman CH,Gardner PA

    更新日期:2014-08-01 00:00:00

  • Evaluation of survivin splice variants in pituitary tumors.

    abstract:PURPOSE:Survivin is an apoptosis inhibitor, expressed in almost all types of human malignancies, but rarely in differentiated normal tissues. Recently, survivin gene splice variants with different anti-apoptotic activities have been reported. The current study was undertaken to examine the expression of survivin and it...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-014-0590-9

    authors: Waligórska-Stachura J,Andrusiewicz M,Sawicka-Gutaj N,Kubiczak M,Jankowska A,Liebert W,Czarnywojtek A,Waśko R,Blanco-Gangoo AR,Ruchała M

    更新日期:2015-06-01 00:00:00

  • The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system.

    abstract:PURPOSE:To evaluate the effects of somatostatin analogs and disease activity status on the upper gastrointestinal system in patients with acromegaly. METHODS:One hundred eighty-one patients with acromegaly were retrospectively assessed. The demographic, biochemical, pathologic, and radiologic data of the patients were...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-020-01095-3

    authors: Sahin S,Icli TB,Durcan E,Sulu C,Ozkaya HM,Hatemi AI,Kadioglu P

    更新日期:2020-10-19 00:00:00

  • Effect of gsp oncogene on somatostatin receptor subtype 1 and 2 mRNA levels in GHRH-responsive GH3 cells.

    abstract::Growth hormone releasing hormone (GHRH) signals via G protein-coupled receptors (GHRH-R) to enhance intracellular Galphas/adenylyl cyclase/cAMP signaling, which in turn has positive effects on GH synthesis and release, as well as proliferation of the GH-producing cells of the anterior pituitary gland. Some GH-producin...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-005-5245-4

    authors: Kim E,Sohn S,Lee M,Park C,Jung J,Park S

    更新日期:2005-01-01 00:00:00

  • Screening for Cushing's syndrome: is it worthwhile?

    abstract:INTRODUCTION:Cushing's syndrome (CS) is a rare disease characterized by a collection of signs and symptoms, also common in the general population without elevated cortisol secretion. During the last years more patients with CS are identified earlier and with milder disease. Many of these patients are diagnosed during s...

    journal_title:Pituitary

    pub_type: 杂志文章,评审

    doi:10.1007/s11102-015-0634-9

    authors: Shimon I

    更新日期:2015-04-01 00:00:00

  • Primary central nervous system lymphoma mimicking pituitary apoplexy: case report.

    abstract::Lymphoma involving the pituitary gland is very rare and usually results from metastatic spread of systemic lymphoma. We present a case of primary central nervous system (CNS) large B cell lymphoma that manifested as pituitary apoplexy. A 45-year-old woman presented with headache, and then rapidly developed a third ner...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-008-0084-8

    authors: Quintero Wolfe S,Hood B,Barker J,Benveniste RJ

    更新日期:2009-01-01 00:00:00

  • A novel variation in the AVP gene resulting in familial neurohypophyseal diabetes insipidus in a large Italian kindred.

    abstract::Familial neurohypophyseal diabetes insipidus (FNDI) is mostly an autosomal dominant inherited disorder presenting with severe polydipsia and polyuria typically in early childhood. To date, 69 different variations in the AVP gene encoding the AVP prohormone have been identified in autosomal dominant FNDI (adFNDI). In t...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-012-0392-x

    authors: Birkegaard C,Christensen JH,Falorni A,Marzotti S,Minarelli V,Gregersen N,Rittig S

    更新日期:2013-06-01 00:00:00

  • Management of aggressive pituitary adenomas: current treatment strategies.

    abstract::Aggressive pituitary adenomas are notoriously difficult to manage due to their size, invasiveness, speed of growth and high frequency of recurrence. Except for prolactinomas, surgery (usually transsphenoidal but sometimes transcranial) is the first-line option, but re-growth of aggressive tumors is almost inevitable a...

    journal_title:Pituitary

    pub_type: 杂志文章,评审

    doi:10.1007/s11102-008-0153-z

    authors: Buchfelder M

    更新日期:2009-01-01 00:00:00

  • Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses.

    abstract::The molecular pathogenesis of prolactinomas has resisted elucidation; with the exception of a RAS mutation in a single aggressive prolactinoma, no mutational changes have been identified. In prolactinomas, a further obstacle has been the paucity of surgical specimens suitable for molecular analysis since prolactionoma...

    journal_title:Pituitary

    pub_type: 杂志文章

    doi:10.1007/s11102-007-0082-2

    authors: Evans CO,Moreno CS,Zhan X,McCabe MT,Vertino PM,Desiderio DM,Oyesiku NM

    更新日期:2008-01-01 00:00:00

  • Leptin and the pituitary.

    abstract::Although leptin was originally viewed as an antiobesity hormone, it is now evident that it may have more pleiotropic actions. Experiments in rodents have shown that leptin activates the sympathetic nervous system, is involved in regulation of blood pressure, hematopoiesis, immune function, angiogenesis and brain, bone...

    journal_title:Pituitary

    pub_type: 杂志文章,评审

    doi:10.1023/a:1012938308654

    authors: Popovic V,Damjanovic S,Dieguez C,Casanueva FF

    更新日期:2001-01-01 00:00:00

  • Management of cystic prolactinomas: a review.

    abstract:INTRODUCTION:Cystic prolactinoma is a variant of prolactin-secreting pituitary adenoma. The strategies for the management of cystic prolactinoma have not been addressed thoroughly in clinical guidelines. METHODS:A literature search was performed using Pubmed to review the current approaches to the treatment of cystic ...

    journal_title:Pituitary

    pub_type: 杂志文章,评审

    doi:10.1007/s11102-018-0888-0

    authors: Nakhleh A,Shehadeh N,Hochberg I,Zloczower M,Zolotov S,Taher R,Daoud Naccache D

    更新日期:2018-08-01 00:00:00